COGT — Cogent Biosciences Inc

Cogent Biosciences Inc (COGT) is a biotechnology company listed on NASDAQ. It is led by Andrew R. Robbins M.B.A., based in 275 Wyman Street, Waltham, MA, United States, 02451, with about 258 employees. Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Net income was -$226.4M. COGT currently screens at market cap $5.75B.

Use this COGT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the COGT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the COGT SEC filings page. Lician reads the product cache first so this HTML stays unique to Cogent Biosciences Inc even when a live quote feed is slow.